Business Context and Reporting Period
This Form 6-K filing by Zai Lab Limited (Zai) covers the month of December 2017, specifically dated December 19, 2017. The filing announces a strategic License and Collaboration Agreement with Five Prime Therapeutics, Inc. (FivePrime) to develop and commercialize FivePrime's proprietary afucosylated FGFR2b antibody, FPA144, in China, Hong Kong, Macau, and Taiwan.
Key Financial Metrics
The filing text does not provide comprehensive financial statements, revenue, profit, cash flow, margins, or debt levels for the reporting period. The only specific financial figures disclosed relate to the new agreement:
- Upfront Payment: $5 million payable by Zai to FivePrime.
- Milestone Payments: Up to $39 million in specified developmental and regulatory milestones per Licensed Product.
- Royalties (Territory): High teens to low twenties percentage on net sales in the Territory, subject to patient enrollment targets.
- Royalties (Outside Territory): Low single-digit percentage on net sales outside the Territory, contingent on Zai's patient enrollment in the FPA144-004 Study.
Material Changes
The primary material change is the execution of the License and Collaboration Agreement on December 19, 2017. This grants Zai exclusive rights to FPA144 in the defined Territory. Zai assumes responsibility for development and commercialization expenses within the Territory and must support FivePrime's global Phase 3 registrational trial (FPA144-004 Study) for front-line gastric and gastroesophageal cancer.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The agreement positions Zai to advance FPA144 in the Asian market while contributing to global development efforts. The term of the agreement expires on a product-by-product and region-by-region basis upon the expiration of payment obligations.
Risks and Contingencies:
- Termination Rights: Zai may terminate the entire agreement with advance written notice. FivePrime may terminate for material breach, failure to meet diligence obligations regarding development or commercialization, or if Zai challenges FivePrime's patents.
- Performance Contingencies: Royalty rates and eligibility for royalties outside the Territory depend on Zai enrolling and treating a specified number of patients in the FPA144-004 Study.
- Insolvency: Either party may terminate upon certain insolvency events involving the other.
Investor Verification Checklist
- Verify the exact patient enrollment thresholds required to secure the low single-digit royalty on sales outside the Territory.
- Confirm the specific breakdown of the $39 million in milestone payments and the clinical/regulatory triggers for each.
- Review the full text of the Agreement (filed as an exhibit to the 2017 Form 20-F) for detailed definitions of "diligence obligations" and termination clauses.
- Assess the impact of the $5 million upfront payment on Zai's current cash position and liquidity.
- Monitor the progress of the FPA144-004 Study in China to evaluate royalty rate adjustments.